title: Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
abstract: Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
authors.forename: Carl
authors.initials: C
authors.lastname: Blomberg
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
authors.forename: Jonas
authors.initials: J
authors.lastname: Nilsson
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiology, Oncology and Radiation Sciences, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Georg
authors.initials: G
authors.lastname: Holgersson
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden.
authors.forename: Per
authors.initials: P
authors.lastname: Edlund
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
authors.forename: Michael
authors.initials: M
authors.lastname: Bergqvist
authors.affiliation: Department of Surgery, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Linda
authors.initials: L
authors.lastname: Adwall
authors.affiliation: Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Simon
authors.initials: S
authors.lastname: Ekman
authors.affiliation: Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Brattström
authors.affiliation: Department of Oncology, Gävle Hospital, Gävle, Sweden Department of Oncology, Uppsala University Hospital, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden stefan.bergstrom@regiongavleborg.se.
authors.forename: Stefan
authors.initials: S
authors.lastname: Bergström
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology; D000086002:Mesothelioma, Malignant; D010166:Palliative Care; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
keywords: Malignant mesothelioma; randomized trials; review